THE EFFECT OF CONCOMITANT ADMINISTRATION OF ERYTHROMYCIN AND DILTIAZEM ON CYP

红霉素和地尔硫卓联合用药对 CYP 的影响

• 批准号: 7717542
• 负责人: STEPHEN D HALL
• 金额: $ 0.18万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-12-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7717542
• 关键词: Area Under Curve; Biological Availability; CYP3A4 gene; CYP3A5 gene; Chronic; Complex; Computer Retrieval of Information on Scientific Projects Database; Diltiazem; Dose; Drug Interactions; Drug Kinetics; Enzymes; Erythromycin; Funding; Grant; Half-Life; Human; In Vitro; Institution; Intestines; Intravenous; Liver; Liver Microsomes; Metabolic; Metabolism; Midazolam; Oral; Pharmaceutical Preparations; Pharmacotherapy; Reporting; Research; Research Personnel; Resources; Site; Source; United States National Institutes of Health; cytochrome P450 3A; drug metabolism; in vivo; inhibitor/antagonist; member; research study

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The cytochrome P450 3A (CYP3A) subfamily of enzymes is one of the most important in drug metabolism and is responsible for the metabolism of a wide variety of endogenous and exogenous compounds. The CYP3A subfamily members (CYP3A4 and CYP3A5) are abundantly expressed in both the liver and small intestinal wall and both are important sites of drug-drug interactions. Erythromycin inhibits CYP3A4 in vitro by forming a metabolic intermediate complex (MIC) in human liver microsomes. Pharmacokinetic demonstrated that erythromycin modestly but significantly altered the pharmacokinetics of intravenous and oral midazolam, producing a 54% reduction in the systemic clearance and a two-fold increase in oral bioavailability of midazolam. Similarly, in-vitro experiments have shown that diltiazem inhibits CYP3A4 by forming an MIC. In-vivo studies report a modest drug-drug interaction between midazolam and diltiazem when both are given orally as a single dose whereby, diltiazem significantly increased the area under the curve and prolonged the elimination half-life of midazolam. However, the effect of the chronic administration of diltiazem on the pharmacokinetics of midazolam is unknown. Moreover, the effects of combining two modest inhibitors on pharmacokinetics of CYP3A substrates are unknown despite the fact that such combinations are commonplace in contemporary pharmacotherapy. Importantly the effects of combinations of inhibitors may be complex and not readily predicted from binary drug-drug interaction studies. To this end, we want to study the effect of erythromycin and diltiazem, alone and in combination, on midazolam pharmacokinetics.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 酶的细胞色素P450 3A（CYP3A）亚家族是药物代谢中最重要的一种，并且负责多种内源性和外源性化合物的代谢。 CYP3A亚家族成员（CYP3A4和CYP3A5）在肝脏和小肠壁上都大量表达，并且都是药物相互作用的重要部位。红霉素通过在人肝微粒体中形成代谢中间复合物（MIC）在体外抑制CYP3A4。 药代动力学表明，红霉素适度但显着改变了静脉内和口服咪达唑仑的药代动力学，从而使系统清除率降低了54％，咪达唑仑口服生物利用度增加了两倍。同样，体外实验表明，diltiazem通过形成MIC抑制CYP3A4。体内研究报告说，当两者以单剂为单剂量给出时，咪达唑仑和diltiazem之间存在适度的药物相互作用，从而使diltiazem显着增加了曲线下的面积并延长了米达唑仑的消除半衰期。但是，diltiazem长期给药对咪达唑仑药代动力学的影响尚不清楚。 此外，尽管这种组合在当代药物疗法中很普遍，但将两个适度抑制剂组合对CYP3A底物药代动力学的影响尚不清楚。重要的是，抑制剂组合的影响可能很复杂，并且不容易预测二元药物 - 药物相互作用研究。为此，我们希望研究红霉素和diltiazem对咪达唑仑药代动力学的影响。